^
    Back
    Association details:
    Biomarker:RET M918T
    Cancer:Thyroid Gland Medullary Carcinoma
    Drug:Gavreto (pralsetinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO Asia 2020
    Title:

    Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

    Published date:
    11/17/2020
    Excerpt:
    We report efficacy for response-evaluable pts (REP) with RET+ MTC and safety for all pts who initiated pralsetinib...In 79 REP with RET+ MTC (mutation: 61% M918T, 28% C634X, 4% V804X, 8% other), ORR was 65% (95% CI 53–75; n=51/79, 5% complete response [CR]; 59% partial response [PR; 1 pending confirmation]).Pralsetinib demonstrated potent and durable clinical activity in RET+ MTC.
    Trial ID:
    ARROW
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Cancer Discov
    Title:

    Precision Targeted Therapy with BLU-667 for RET-Driven Cancers

    Excerpt:
    A 27-year-old patient with sporadic MTC harboring multiple RET mutations (L629P, D631_R635DELINSG, and V637R)…This patient remains progression free and on therapy for more than 11 months.
    DOI:
    10.1158/2159-8290.CD-18-0338